prostate cancer
The Challenge
In preparation of the launch innovative therapy for prostate cancer, a global biopharmaceutical company sought to identify, establish, and enhance vital relationships with key stakeholders. This encompassed policy decision-makers, patient organizations, and other influential figures within the realm of men's health.
Our Solution
Identified key policy decision-makers, patient organizations, and other influencers in the United States, Europe, and Latin America.
Conducted competitive intelligence to understand current industry activities and identify gaps, unmet needs, and opportunities.
Orchestrated a dedicated European Patient Advisory Board concentrated on prostate cancer to gain insights into critical unmet needs.
Defined comprehensive stakeholder engagement plans to guide company activities and advocacy collaborations tailored to each region.
Created and led the company’s first Prostate Cancer Advocacy Steering Committee (ongoing).
Benefit to Client
Amplified Stakeholder Engagement Pathways: Enhanced avenues for engagement with key prostate cancer advocacy stakeholders.
In-depth Understanding of Unmet Needs: Obtained a better understanding of key unmet needs that men still face when confronted with prostate cancer, encompassing low awareness or risk, low screening rates, subpar symptom management after treatment, and the constraining stigma that hampers discussions and support throughout diagnosis, treatment, and care.
Effective Competitive Distinctiveness and Reputation Enhancement: Differentiation from competitors and elevation of reputation among a diverse range of external stakeholders.
Strengthened Relationships: New and strengthened relationships with leading patients and influential advocates within the prostate cancer realm.
Collaboration Opportunities: Ability to co-create patient support tools and resources.
Support Strategies and Interventions: Approaches to better support patients and caregivers, address health disparities, understand access issues, and determine treatment pathways for late-stage prostate cancer.